Amyotrophic lateral sclerosis or ALS is a neurodegenerative disorder/disease, which is a most common type of motor neuron disease (MND). ALS can occur in humans due to mutations in the gene that encodes the enzyme copper-zinc superoxide dismutase (CuZnSOD), which is associated with defect in chromosome & genetic inheritance. This type disease is more common in men. These abnormalities are caused by heredity and genetic mutations that lead to the release of glutamate, which damages the motor neurons that control voluntary muscles. Some common symptoms of ALS include respiratory problems, cramps, spasticity, muscles weakness, and fasciculation.
ALS drugs are used in specialized centers, hospitals, research& academic institutes, where hospital pharmacies are the largest consumers of ALS drugs, and the demand for them is expected to grow. There is an increasing preference in patients for retail pharmacies and hospital pharmacies. This can be seen as an easy and quick way to gain access to a wide range of drugs and products offered through distribution channels.
As per analysis, “Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Region: Trend Outlook and Growth Opportunity” some of the leading enterprises that are presently working in the ALS treatment market are Biohaven Pharmaceutical Holding Co., Ltd., AB Science SA, Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., Biogen Inc., F.Hoffmann-La Roche AG, Corestem, Inc., Otsuka Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc., BrainStorm Cell Limited and among others.
Based on treatment type, market can be segregated as stem cell therapy, medication (Nuedexta, Radicava (Edaravone), Riluzole (Rilutek), and Tiglutik (Thickened Riluzole) and others. Stem cell therapy segment dominates the market owing to rise in demand for new approaches & advanced treatment options. Based on ALS type, market can be segregated as familial ALS and sporadic ALS. Additionally, based on application, market can be segregated as online pharmacies, retail pharmacies, hospital pharmacies and other distribution channel.
Rise in the incidence of amyotrophic lateral sclerosis, followed by growth in geriatric population and rise in the awareness about amyotrophic lateral sclerosis are some major factors, which are responsible for growth of the market. Apart from this, limited availability of treatment options is a major hindering factor for market. Moreover, growth in inclination toward sedentary lifestyle is a key opportunity for market.
Based on regional analysis, the North-America is a leading region in global market owing to rise in demand for ALS drugs, favorable reimbursement policies, high healthcare expenditure, and established healthcare infrastructure across the region. In addition, public and private organizations are entering into partnerships and strategic partnerships to improve ALS treatment outcomes in the region. The Europe and Asia-Pacific regions are estimated to witness higher growth rate due to plenty of unexplored opportunities, growth in research & development (R&D) investment in the healthcare sector, and promising initiatives by the manufacturers & governments over the forecast period. It is predicted that future of the global market will be bright as a result of rise in the awareness about amyotrophic lateral sclerosis coupled with growth in inclination toward sedentary lifestyle during the forecast period.
For More Information, click on the link below:-
North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Country: Trend Outlook and Growth Opportunity
Ankur Gupta, Head Marketing & Communications